Cetera Advisor Networks LLC increased its holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL – Get Rating) by 68.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 53,653 shares of the biotechnology company’s stock after buying an additional 21,785 shares during the quarter. Cetera Advisor Networks LLC owned 0.07% of Anavex Life Sciences worth $660,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Brookstone Capital Management raised its position in shares of Anavex Life Sciences by 6.4% during the first quarter. Brookstone Capital Management now owns 14,829 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 893 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its position in Anavex Life Sciences by 4.3% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 24,209 shares of the biotechnology company’s stock worth $420,000 after purchasing an additional 1,000 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in Anavex Life Sciences by 6.2% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 17,885 shares of the biotechnology company’s stock worth $310,000 after purchasing an additional 1,044 shares during the last quarter. AllSquare Wealth Management LLC increased its position in Anavex Life Sciences by 2.5% during the first quarter. AllSquare Wealth Management LLC now owns 65,956 shares of the biotechnology company’s stock valued at $812,000 after acquiring an additional 1,605 shares during the last quarter. Finally, HighTower Advisors LLC boosted its stake in shares of Anavex Life Sciences by 21.2% during the fourth quarter. HighTower Advisors LLC now owns 10,278 shares of the biotechnology company’s stock valued at $178,000 after purchasing an additional 1,800 shares during the period. Hedge funds and other institutional investors own 31.93% of the company’s stock.
Wall Street Analyst Weigh In
Separately, Berenberg Bank assumed coverage on shares of Anavex Life Sciences in a report on Thursday, June 23rd. They set a “buy” rating and a $40.00 price objective on the stock.
Anavex Life Sciences Stock Down 2.7 %
Anavex Life Sciences (NASDAQ:AVXL – Get Rating) last issued its earnings results on Tuesday, August 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). During the same period last year, the business earned ($0.14) earnings per share. As a group, research analysts predict that Anavex Life Sciences Corp. will post -0.6 EPS for the current fiscal year.
Anavex Life Sciences Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex.
- Get a free copy of the StockNews.com research report on Anavex Life Sciences (AVXL)
- 3 Low Beta Defensive Stocks for a Tough Market
- It Could Be a September to Remember for These 3 Stocks
- Peak Inflation Sets the Bottom for Brinker International Stock
- Can Roblox Reverse its Falling Bookings Amid Rising Engagements
- Broadcom Bounces From Institutional Bottom
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.